TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive In Brief: Grants To Get Biggest Share Of NCI’s Extra $74 Million; A PR Failure In Pittsburgh March 19, 1976
